Every 8-K that Oscar Health, Inc. (OSCR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OSCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OSCR filings page.
Oscar Health, Inc. (OSCR) announced updated full year 2026 guidance in connection with its Investor Day, including higher expected profitability and slightly improved medical cost ratios. The company now expects Earnings from Operations between $600 million and $800 million, up by $100 million from the prior range of $500 million to $700 million.
Oscar also tightened its expected Medical Loss Ratio to 81.0%–82.0%, improving this range by 50 basis points from its previous 81.5%–82.5% outlook. The company reaffirmed its 2026 guidance for Total Revenue of $18.7 billion to $19.0 billion and an SG&A Expense Ratio of 15.6%–16.1%. Management plans to discuss strategy, long-term financial targets, and this updated outlook at its September 16, 2026 Investor Day, with materials and a webcast available on its investor relations website.
Oscar Health reported record profitability in the first half of 2026. For Q2 2026, total revenue was $4,880,220 (in thousands) and net income attributable to Oscar Health, Inc. was $361,808 (in thousands), compared with a net loss of $228,361 (in thousands) a year earlier. Earnings from operations were $388,635 (in thousands) and Adjusted EBITDA reached $415,349 (in thousands). Medical loss ratio improved to 79.2% from 91.1%, and the SG&A expense ratio fell to 14.2% from 18.7%, helped by disciplined pricing, $164 million of favorable prior-period reserve development, and expense control.
For the first six months of 2026, net income attributable to Oscar Health, Inc. was $1,040,804 (in thousands) and Adjusted EBITDA was $1,142,421 (in thousands). Effectuated membership rose to 2,963,002 as of June 30, 2026. The company raised its full-year 2026 outlook, keeping total revenue guidance at $18.7–$19.0 billion but increasing expected earnings from operations to $500–$700 million and tightening MLR and SG&A expense ratio ranges. Cash and cash equivalents increased to $4,075,612 (in thousands), supporting a stronger balance sheet.
Oscar Health, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders elected eight directors to serve until the 2027 Annual Meeting, with each nominee receiving over 770 million votes when including high-vote Class B shares.
Stockholders approved, on an advisory basis, the compensation of the company’s named executive officers, with 765,188,330 votes in favor, 8,859,050 against, and 329,648 abstaining. They also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026, with 819,470,681 votes for and 710,425 against.
Oscar Health, Inc. announced it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, where it plans to provide a business update and reaffirm its full year 2026 guidance previously issued on February 10, 2026.
A live audio webcast will be available on the company’s investor relations website, with a replay accessible for about 90 days. The company also reminds readers that statements about expected financial performance are forward-looking and subject to risks described in its Form 10-K for 2025 and Form 10-Q for the quarter ended March 31, 2026.
Oscar Health, Inc. has amended and restated the employment agreement for co-founder Mario Schlosser, effective June 1, 2026, as he transitions from President of Technology and Chief Technology Officer to Co-Founder & Advisor to the CEO. In his new role, he will focus on accelerating the company’s artificial intelligence and digital health initiatives and will remain on the Board of Directors.
Under the new agreement, Mr. Schlosser’s annual base salary will be $370,000. Beginning with calendar year 2026, he will no longer be eligible for an annual bonus or for new long-term incentive or equity-based awards, although his existing equity awards will continue to vest under their current terms. He will also not be entitled to cash severance payments or company-subsidized healthcare coverage upon any termination of employment.
Oscar Health, Inc. reported strong results for the quarter ended March 31, 2026, and reaffirmed its full-year 2026 guidance. Total revenue reached $4.6 billion, up from $3.0 billion a year earlier, driven by higher membership and rate increases.
The medical loss ratio improved to 70.5% from 75.4%, and the SG&A expense ratio edged down to 15.2% from 15.8%, reflecting disciplined pricing and cost control. Earnings from operations were $704.1 million, with net income attributable to Oscar of $679.0 million, or $2.07 diluted EPS, versus $275.3 million, or $0.92, in 2025.
Adjusted EBITDA was $727.1 million, up from $328.8 million. Membership rose to 3.17 million from 2.04 million, entirely in Individual and Small Group offerings following the end of the Cigna+Oscar arrangement. Cash, cash equivalents and restricted cash increased to $4.83 billion as operating cash flow strengthened.
Oscar Health, Inc. reaffirmed its full year 2026 guidance that was originally provided with its fourth quarter and full year 2025 results. The company also reminded investors it plans to release first quarter 2026 financial results before the market opens on May 6, 2026, followed by a conference call at 8:00 AM (ET).
Oscar announced that independent director Siddhartha Sankaran will become Chair of the Board effective June 4, 2026, succeeding Jeffery Boyd, who is not standing for reelection at the upcoming annual meeting. The company highlights Sankaran’s extensive insurance industry and board experience, and both Boyd and Sankaran emphasize Oscar’s positioning for future growth and its role in the individual health insurance market.
Oscar Health, Inc. is confirming that its previously issued full-year 2026 financial guidance remains in place as it participates in the 2026 Raymond James Institutional Investors Conference on March 2, 2026. The guidance being reaffirmed was first provided in its February 10, 2026 press release covering fourth-quarter and full-year 2025 results.
The company also reminds readers that these expectations are forward-looking statements subject to risks and uncertainties described in its Annual Report on Form 10-K for the year ended December 31, 2025 and other SEC filings.
Oscar Health, Inc. reported strong top-line growth but a sharp swing back to losses in 2025 and set an optimistic 2026 outlook, while adding a large new credit facility.
Full-year 2025 total revenue rose to $11.7 billion from $9.2 billion, driven by higher membership. However, the medical loss ratio worsened to 87.4% from 81.7%, and earnings from operations fell to a $396.4 million loss from $57.3 million of earnings. Net loss attributable to Oscar was $443.2 million versus net income of $25.4 million in 2024, and Adjusted EBITDA deteriorated to a $279.8 million loss from $199.2 million of positive Adjusted EBITDA.
Membership reached about 2.0 million as of December 31, 2025, with Individual and Small Group members rising to just over 2.0 million. For 2026, Oscar guides to total revenue of $18.7–$19.0 billion, a medical loss ratio of 82.4–83.4%, an SG&A ratio of 15.8–16.3%, and $250–$450 million of earnings from operations, implying a planned return to profitability. The company also entered into a new $475 million secured revolving credit facility, expandable by up to $100 million, maturing on February 6, 2029, with financial covenants tied to premiums, liquidity, leverage, and coverage ratios.
Oscar Health, Inc. disclosed that it entered into an amended and restated employment agreement with Mark T. Bertolini effective December 22, 2025. The new agreement runs through April 1, 2029, providing a multi-year commitment, and then automatically renews for additional one-year periods unless either party decides not to extend it. The company also notes that, apart from specified 2026 long-term incentive awards, Mr. Bertolini is not expected to receive additional long-term incentive or equity-based awards before calendar year 2029.
Oscar Health (OSCR) entered an Exchange Agreement with Dragoneer, allowing exchanges of up to $250,000,000 principal of 7.25% convertible senior notes due 2031 through December 14, 2025. On November 5, 2025, Dragoneer exchanged $187,500,000 of these notes for 23,273,179 Class A shares, and the company was relieved of future interest payments on the exchanged debt.
The Agreement also provides for up to $17.8 million of additional consideration, payable in shares and/or cash, pursuant to its terms and conditions. As of November 5, 2025, debt covenants in the 2031 notes Investment Agreement were extinguished, and the company’s $410,000,000 2.25% convertible senior subordinated notes due 2030 ceased to be subordinated to the 2031 notes.
Separately, the company furnished a press release announcing financial results for the quarter ended September 30, 2025 as Exhibit 99.1.
Oscar Health, Inc. filed an 8-K reporting execution of an Indenture dated September 18, 2025 between the company and U.S. Bank Trust Company, National Association as trustee. The filing includes the form of certificate for 2.25% Convertible Senior Subordinated Notes due 2030 (Exhibit A to Exhibit 4.1) and a form of Capped Call Confirmation. The submission also contains the cover page interactive data file embedded in the inline XBRL document. The filing is signed by R. Scott Blackley, Chief Financial Officer.
Oscar Health, Inc. filed an 8-K reporting that it has given notice of its intent to terminate the revolving credit facility that is part of its senior secured credit agreement with Wells Fargo Bank, N.A. and other lenders; the termination is contingent on the closing of an offering and will occur concurrently with that closing. The company disclosed an offering of notes to qualified institutional buyers under Rule 144A, and attached a press release as Exhibit 99.1. The report is signed by R. Scott Blackley, Chief Financial Officer and dated September 16, 2025.
Oscar Health, Inc. disclosed an amendment to its January 27, 2022 Investment Agreement with Dragoneer-affiliated funds to permit an offering of securities. The filing states the company expects to terminate its revolving credit facility concurrently with the closing of the offering; that termination is contingent on the offering closing. The offering is described as a Rule 144A placement to qualified institutional buyers. A press release dated September 15, 2025 is attached as Exhibit 99.1 and the report is signed by Chief Financial Officer R. Scott Blackley.
Oscar Health, Inc. plans to take part in the 2025 Wells Fargo Healthcare Conference on September 3, 2025, where it will reaffirm the updated full-year 2025 guidance it previously shared in its July 22, 2025 preliminary second-quarter results press release. This means the company is publicly standing by its current 2025 financial outlook when speaking with investors at the event.
The company also reminds readers that any statements about expected financial performance are forward-looking and subject to risks and uncertainties described in its recent annual and quarterly reports filed with the SEC.
Oscar Health, Inc. (OSCR) filed a Form 8-K on 22 Jul 2025 to notify investors that it has issued a press release containing preliminary second-quarter 2025 results and a revised full-year 2025 outlook. The press release is furnished as Exhibit 99.1 and, per the filing, is not deemed “filed” under Exchange Act Section 18. No quantitative metrics, guidance figures, or additional material events are included in the body of the 8-K. Other than furnishing the exhibit, the company reported no changes to previously disclosed risk factors, transactions, or governance matters.